Relevant bibliographies by topics / Therapeutics

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Therapeutics'

Author: Grafiati
Published: 4 June 2021
Last updated: 30 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Therapeutics.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Therapeutics"

1

Misselbrook, David. "Therapeutics?" British Journal of General Practice 71, no. 713 (November 25, 2021): 553. http://dx.doi.org/10.3399/bjgp21x717845.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Azimi, A., S. Kuznecovs, J. Kuznecovs, A. Blazejczyk, M. Switalska, S. Chlopicki, A. Marcinek, et al. "Therapeutics." Annals of Oncology 23, suppl 5 (June 1, 2012): v23—v32. http://dx.doi.org/10.1093/annonc/mds162.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Joyce, David A., and Kenneth F. Ilett. "Therapeutics." Medical Journal of Australia 161, no. 10 (November 1994): 622–26. http://dx.doi.org/10.5694/j.1326-5377.1994.tb127645.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Zipursky, Robert. "THERAPEUTICS." Schizophrenia Research 153 (April 2014): S65. http://dx.doi.org/10.1016/s0920-9964(14)70209-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Van Zeeland, Yvonne R. A. "Therapeutics." Veterinary Clinics of North America: Exotic Animal Practice 21, no. 2 (May 2018): i. http://dx.doi.org/10.1016/s1094-9194(18)30020-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

van Zeeland, Yvonne R. A. "Therapeutics." Veterinary Clinics of North America: Exotic Animal Practice 21, no. 2 (May 2018): xiii—xv. http://dx.doi.org/10.1016/j.cvex.2018.02.001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Alisi, Anna, Sara Tomaselli, Clara Balsano, and Angela Gallo. "Hepatitis C virus therapeutics: Editing enzymes promising therapeutic targets?" Hepatology 54, no. 2 (July 25, 2011): 742. http://dx.doi.org/10.1002/hep.24409.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Barish, Robert A., and Jerome F. X. Naradzay. "Ophthalmologic Therapeutics." Emergency Medicine Clinics of North America 13, no. 3 (August 1995): 649–67. http://dx.doi.org/10.1016/s0733-8627(20)30611-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Greish, Khaled, Jun Fang, Takao Inutsuka, Akinori Nagamitsu, and Hiroshi Maeda. "Macromolecular Therapeutics." Clinical Pharmacokinetics 42, no. 13 (2003): 1089–105. http://dx.doi.org/10.2165/00003088-200342130-00002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Katsarou, Angeliki, and Kostas Pantopoulos. "Hepcidin Therapeutics." Pharmaceuticals 11, no. 4 (November 21, 2018): 127. http://dx.doi.org/10.3390/ph11040127.

Full text
Abstract:
Hepcidin is a key hormonal regulator of systemic iron homeostasis and its expression is induced by iron or inflammatory stimuli. Genetic defects in iron signaling to hepcidin lead to “hepcidinopathies” ranging from hereditary hemochromatosis to iron-refractory iron deficiency anemia, which are disorders caused by hepcidin deficiency or excess, respectively. Moreover, dysregulation of hepcidin is a pathogenic cofactor in iron-loading anemias with ineffective erythropoiesis and in anemia of inflammation. Experiments with preclinical animal models provided evidence that restoration of appropriate hepcidin levels can be used for the treatment of these conditions. This fueled the rapidly growing field of hepcidin therapeutics. Several hepcidin agonists and antagonists, as well as inducers and inhibitors of hepcidin expression have been identified to date. Some of them were further developed and are currently being evaluated in clinical trials. This review summarizes the state of the art.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Therapeutics"

1

Lopez, Aguilar Aime. "Peptides as therapeutics." Thesis, University of Oxford, 2011. http://ora.ox.ac.uk/objects/uuid:d893e962-5cb9-4d50-bbe1-c5183418295c.

Full text
Abstract:
Peptides have attracted increasing attention as therapeutics in recent years, at least partially as a consequence of the widespread acceptance of protein therapeutics; but also as possible solutions to problems such as short half-life and delivery of molecules, and as therapeutics in their own right. The current work presents three projects that involve applications of peptides in a therapeutic environment. The first project studies the use of ER retaining peptides and CPPs (Cell penetrating peptides) in enhancing the effective concentration of DNJ (1-deoxynojirimycin), an α-glucosidase inhibitor, in cells. DNJ constructs with ER retaining peptides (6-[N-(1-deoxynojirimycino)]-hexanoyl-KDEL and 6-[N-(1-deoxynojirimycino)]-hexanoyl-KKAA) and CPPs (6-[N-(1-deoxynojirimycino)]-hexanoyl-TAT and 6-[N-(1-deoxynojirimycino)]-hexanoyl-MAP) were synthesised and analysed for their inhibitory activity against α-glucosidase I and II in vitro. The constructs were then analysed in a cell-based assay to determine their inhibitory activity on α¬-glucosidase-mediated hydrolysis of N-linked oligosaccharides. FITC-labelled ER retaining peptides were also synthesised to determine the internalisation and trafficking of the constructs by FACS and IF-microscopy. While none of the DNJ-constructs showed higher cellular inhibition than NB-DNJ (N-butyl DNJ; Miglustat), the CPP construct 6-[N-(1-deoxynojirimycino)]-hexanoyl-TAT showed comparable activity and the ER retaining construct 6-[N-(1-deoxynojirimycino)]-hexanoyl-KDEL showed a small but significant increase in activity following long-term administration. The second project focuses on beauveriolides, a cyclic depsipeptide family shown to have activity as ACAT inhibitors and thus a possible treatment for Alzheimer’s disease by the decrease in the production of Amyloid β (Aβ). A published total synthetic method was improved by the use of a cross-metathesis to reduce the total synthesis by 5 steps and increase its flexibility to allow the production of analogues. The synthesised beauveriolide III was used in attempts to develop an IF-FACS-based assay to measure the intracellular concentrations of Aβ. However, the location of γ-secretase in the used cell-line meant that levels of intracellular Aβ were not sufficient to track any decrease caused by ACAT inhibition. The third project involves the design of a cyclic peptide that could block the binding site for the influenza virus in the host cell. The cyclic peptide (cGSGRGYGRGWGVGA) was developed from a comparative study of four different sialic acid-binding proteins and synthesised by solution cyclisation of the linear peptide synthesised by traditional solid phase peptide synthesis (SPPS). An in silico study showed that the cyclic peptide allowed overlap with the binding site of Hemagglutinin. A 1H NMR titration determined the dissociation constant of the cyclic peptide to sialic acid. The KD corresponded to a low binding affinity, however the observed binding seemed to be specific and caused by a single bound conformation.
APA, Harvard, Vancouver, ISO, and other styles
2

Balivada, Sivasai. "Cell mediated therapeutics for cancer treatment: tumor homing cells as therapeutic delivery vehicles." Diss., Kansas State University, 2013. http://hdl.handle.net/2097/16890.

Full text
Abstract:
Doctor of Philosophy
Department of Anatomy and Physiology
Deryl L. Troyer
Many cell types were known to have migratory properties towards tumors and different research groups have shown reliable results regarding cells as delivery vehicles of therapeutics for targeted cancer treatment. Present report discusses proof of concept for 1. Cell mediated delivery of Magnetic nanoparticles (MNPs) and targeted Magnetic hyperthermia (MHT) as a cancer treatment by using in vivo mouse cancer models, 2. Cells surface engineering with chimeric proteins for targeted cancer treatment by using in vitro models. 1. Tumor homing cells can carry MNPs specifically to the tumor site and tumor burden will decrease after alternating magnetic field (AMF) exposure. To test this hypothesis, first we loaded Fe/Fe3O4 bi-magnetic NPs into neural progenitor cells (NPCs), which were previously shown to migrate towards melanoma tumors. We observed that NPCs loaded with MNPs travel to subcutaneous melanoma tumors. After alternating magnetic field (AMF) exposure, the targeted delivery of MNPs by the NPCs resulted in a mild decrease in tumor size (Chapter-2). Monocytes/macrophages (Mo/Ma) are known to infiltrate tumor sites, and also have phagocytic activity which can increase their uptake of MNPs. To test Mo/Ma-mediated MHT we transplanted Mo/Ma loaded with MNPs into a mouse model of pancreatic peritoneal carcinomatosis. We observed that MNP-loaded Mo/Ma infiltrated pancreatic tumors and, after AMF treatment, significantly prolonged the lives of mice bearing disseminated intraperitoneal pancreatic tumors (Chapter-3). 2. Targeted cancer treatment could be achieved by engineering tumor homing cell surfaces with tumor proteases cleavable, cancer cell specific recombinant therapeutic proteins. To test this, Urokinase and Calpain (tumor specific proteases) cleavable; prostate cancer cell (CaP) specific (CaP1 targeting peptide); apoptosis inducible (Caspase3 V266ED3)- rCasp3V266ED3 chimeric protein was designed in silico. Hypothesized membrane anchored chimeric protein (rCasp3V266ED3, rMcherry red) plasmids were constructed. Membrane anchoring and activity of designed proteins were analyzed in RAW264.7 Mo/Ma and HEK293 cells in vitro. Further, Urokinase (uPA) mediated cleavage and release of rCasp3V266ED3 from engineered cells was tested (Chapter-4). Animal models for cancer therapy are invaluable for preclinical testing of potential cancer treatments. Final chapter of present report shows evidence for immune-deficient line of pigs as a model for human cancers (Chapter-5)
APA, Harvard, Vancouver, ISO, and other styles
3

Gunnam, Mallikarjunareddy. "Novel anti-norovirus therapeutics." Thesis, Wichita State University, 2013. http://hdl.handle.net/10057/6818.

Full text
Abstract:
Noroviruses are the most common cause of acute gastroenteritis, accounting for over 23 million cases annually in the U.S. alone. Norovirus infections constitute an important health problem for which there are no specific antiviral therapeutics or vaccines. In this thesis, (a) structure-activity relationship studies were carried out using the acyclic sulfamide scaffold. Several derivatives based on this scaffold were found to inhibit norovirus in a cell-based replicon system and, (b) a series of bisulfite adducts derived from representative transition state inhibitors (dipeptidyl aldehydes and ?-ketomides) was synthesized and shown to exhibit anti-norovirus activity in a cell-based replicon system. The ED50 of the most effective inhibitor was 60 nM. This study demonstrates for the first time the utilization of bisulfite adducts of transition inhibitors in the inhibition of norovirus 3CL protease in vitro and in a cell-based replicon system. The approach described herein can be extended to the synthesis of the bisulfite adducts of other classes of transition state inhibitors of serine and cysteine proteases, such as ?-ketoheterocycles and ?-ketoesters. Taken together, this thesis describes the discovery of two novel classes of inhibitors of noroviruses.
Thesis (M.S.)--Wichita State University, Fairmount College of Liberal Arts and Sciences, Dept. of Chemistry
APA, Harvard, Vancouver, ISO, and other styles
4

Hill, Jonathan B. "Deoxyvariolins and polymer therapeutics." Thesis, University of Canterbury. Chemistry, 2005. http://hdl.handle.net/10092/6695.

Full text
Abstract:
Polymeric carrier molecules have been shown to improve the pharmacokinetics and pharmacological profile of small-molecule anticancer drugs. The variolins are a group of marine natural product-derived cytotoxins whose clinical efficacy may be improved through conjugation with a polymer backbone. This thesis first describes the optimisation of a synthesis of the non-natural analogue deoxyvariolin B, a synthesis that was devised by Anderson and Morris immediately prior to the commencement of this project. The synthesis, comprised of six linear steps, was refined to give an overall yield of 25%. As part of a much larger structure-activity relationship investigation being carried out by Pharma Mar, SA (a Spanish pharmaceutical company specialising in marine natural products), a small library of deoxyvariolin analogues, numbering approximately fifteen, was also synthesised and tested in vitro against the P388 murine leukaemia cell line. All analogues synthesised showed an appreciable loss of bioactivity (typically around an order of magnitutude) compared to that of deoxyvariolin B, Attempts at acylating deoxyvariolin B with the tetrapeptide biolinker were hampered by DVB's awkward reactivity and the low stability of some of the products. A more suitable deoxyvariolin analogue, in terms of its bioactivity as well as chemical reactivity, was therefore chosen for development into a polymer therapeutic. This analogue was successfully conjugated with a tetrapeptide biolinker to give a compararably bioactive conjugate that was to be reacted with an activated polymer backbone. The final part of this thesis, however, describes work that was carried out with the polymeric starting material, in which it was revealed that two unforeseen side reactions were taking place. These side reactions ultimately precluded the synthesis of the target constructs.
APA, Harvard, Vancouver, ISO, and other styles
5

Reynolds, Francis M. M. B. A. Massachusetts Institute of Technology. "InVivo Therapeutics® Corporation." Thesis, Massachusetts Institute of Technology, 2006. http://hdl.handle.net/1721.1/37231.

Full text
Abstract:
Thesis (M.B.A.)--Massachusetts Institute of Technology, Sloan School of Management, 2006.
Includes bibliographical references (leaf 100).
To date, the primary treatment for spinal cord injuries has been the use of spinal fixation devices to create a stable environment for the spinal cord to heal. The second treatment option is to remove soft tissue near and around the spinal cord intended to reduce pressure on the spinal cord and allow the spinal cord to heal on its own. InVivo Therapeutics Corporation is a startup founded to commercialize novel science and technology that was developed through a collaborative effort between the Massachusetts Institute of Technology's Langer labs, and the department of Neuroscience at Harvard Medical School. Together they have created a patent pending medical device that will provide the first "Neuro-Tissue Engineered" implantable device for the immediate treatment of spinal cord injuries. We expect to have our first product on the market in 2010, and we will continue to work in our labs to develop a portfolio of three to four product categories in order to meet the systemic needs of the spinal cord injury patient. This thesis presents the first business plan, to commercialize this innovative treatment option.
(cont.) It is always challenging to be first to market with such an innovative product, so we have meticulously explored all relevant strategic initiatives, and tactical tasks required to bring our products to market. As the result we have developed a comprehensive business plan to ensure InVivo's success. Key components of the plan are: Introduction to InVivo Therapeutics, InVivo's business model, critical strategic analysis, functional strategies, financial analysis, and an integrative strategic framework. We have created a vision, mission, and strategic model that will lead to InVivo Therapeutics becoming a global leader in the treatment of neurological disease.
by Francis M. Reynolds.
M.B.A.
APA, Harvard, Vancouver, ISO, and other styles
6

O'Malley, Jennifer A. "Improving therapeutics for Parkinson's disease." Cincinnati, Ohio : University of Cincinnati, 2009. http://rave.ohiolink.edu/etdc/view.cgi?acc_num=ucin1259079683.

Full text
Abstract:
Thesis (Ph.D.)--University of Cincinnati, 2009.
Advisor: Kathy Steece-Collier. Title from electronic thesis title page (viewed Apr. 26, 2010). Keywords: Parkinson; dopamine; dyskinesia; levodopa; dendritic spine; medium spiny neuron. Includes abstract. Includes bibliographical references.
APA, Harvard, Vancouver, ISO, and other styles
7

Langford, Nigel James. "Beta-receptor pharmacology and therapeutics." Thesis, University of Birmingham, 2003. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.404060.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Derfus, Austin Matthew. "Toward multifunctional nanoparticle-based therapeutics." Diss., Connect to a 24 p. preview or request complete full text in PDF format. Access restricted to UC campuses, 2006. http://wwwlib.umi.com/cr/ucsd/fullcit?p3254426.

Full text
Abstract:
Thesis (Ph. D.)--University of California, San Diego, 2006.
Title from first page of PDF file (viewed May 3, 2007). Available via ProQuest Digital Dissertations. Vita. Includes bibliographical references (p. 121-135).
APA, Harvard, Vancouver, ISO, and other styles
9

Sutter, Julianne V. "ASSESSING IMPACT OF AFFECT RECOGNITION ON THERAPEUTIC RELATIONSHIP." UKnowledge, 2010. http://uknowledge.uky.edu/gradschool_theses/14.

Full text
Abstract:
Therapeutic alliance and its relationship to client nonverbal behavior, specifically facial expressions, were examined. Therapist interpretation of the client nonverbal behavior, or affect, influences the therapeutic alliance and process. Based on a sample of clients from a graduate school therapy training facility, results suggest therapist training in facial expressions, and how they relate to client emotion, improve the therapeutic alliance between therapist and client. After a micro-expression training for therapists, clients reported higher life functioning on the Outcome Rating Scale (ORS) and an improved therapeutic alliance on the Session Rating Scale (SRS). Overall, these findings support the benefit of incorporating micro-expression training into therapy instruction.
APA, Harvard, Vancouver, ISO, and other styles
10

Chiu, Shih-Jiuan. "Receptor-mediated DNA-based therapeutics delivery." Columbus, Ohio : Ohio State University, 2005. http://rave.ohiolink.edu/etdc/view?acc%5Fnum=osu1127403022.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Therapeutics"

1

A, Fronefield Stephen, ed. Therapeutics. Philadelphia: Saunders, 2000.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Agrawal, Sudhir. Antisense Therapeutics. New Jersey: Humana Press, 1996. http://dx.doi.org/10.1385/0896033058.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Teicher, Beverly A. Cancer Therapeutics. New Jersey: Humana Press, 1996. http://dx.doi.org/10.1385/0896034607.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Phillips, M. Ian. Antisense Therapeutics. New Jersey: Humana Press, 2004. http://dx.doi.org/10.1385/1592598544.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Allerton, Charlotte, ed. Pain Therapeutics. Cambridge: Royal Society of Chemistry, 2013. http://dx.doi.org/10.1039/9781849737715.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Sverdlov, Oleksandr, and Joris van Dam. Digital Therapeutics. Boca Raton: Chapman and Hall/CRC, 2022. http://dx.doi.org/10.1201/9781003017288.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Jois, Seetharama D., ed. Peptide Therapeutics. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-04544-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Srivastava, Ved, ed. Peptide Therapeutics. Cambridge: Royal Society of Chemistry, 2019. http://dx.doi.org/10.1039/9781788016445.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Vaughan, Tristan, Jane Osbourn, and Bahija Jallal, eds. Protein Therapeutics. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA, 2017. http://dx.doi.org/10.1002/9783527699124.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Teicher, Beverly A., ed. Cancer Therapeutics. Totowa, NJ: Humana Press, 1997. http://dx.doi.org/10.1007/978-1-59259-717-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Therapeutics"

1

Louie, A. H. "Therapeutics." In IFSR International Series on Systems Science and Engineering, 223–34. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4614-6928-5_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Liu, Zhanwen. "Therapeutics." In Essentials of Chinese Medicine, 321–50. London: Springer London, 2009. http://dx.doi.org/10.1007/978-1-84882-590-1_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Elliott, Peter G. "Therapeutics." In MRCGP, 64–80. London: Springer London, 1989. http://dx.doi.org/10.1007/978-1-4471-1710-0_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Myers, Michael T. "Therapeutics." In COVID-ology, 75–102. Boca Raton: CRC Press, 2022. http://dx.doi.org/10.1201/9781003310525-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Liu, Zhanwen. "Therapeutics." In Essentials of Chinese Medicine, 321–50. London: Springer London, 2010. http://dx.doi.org/10.1007/978-1-84882-112-5_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Rosenberg, Paul A. "Therapeutics." In Endodontic Pain, 159–76. Berlin, Heidelberg: Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-642-54701-0_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Niazi, Sarfaraz K. "RNA Therapeutics." In mRNA Therapeutics, 67–106. Boca Raton: CRC Press, 2022. http://dx.doi.org/10.1201/9781003248156-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Stein, Cy A., Britta Hoehn, and John Rossi. "Oligonucleotide Therapeutics." In Principles of Anticancer Drug Development, 569–87. New York, NY: Springer New York, 2010. http://dx.doi.org/10.1007/978-1-4419-7358-0_20.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Schellekens, Huub. "Recombinant Therapeutics." In Encyclopedia of Cancer, 1–3. Berlin, Heidelberg: Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-642-27841-9_4994-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Jain, Kewal K. "Cardiovascular Therapeutics." In Applications of Biotechnology in Cardiovascular Therapeutics, 1–27. Totowa, NJ: Humana Press, 2011. http://dx.doi.org/10.1007/978-1-61779-240-3_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Therapeutics"

1

Anders, J. "Emerging Photobiomodulation Therapeutics." In CLEO: Applications and Technology. Washington, D.C.: OSA, 2017. http://dx.doi.org/10.1364/cleo_at.2017.atu3a.1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Dormer, Kenneth, Sunny Po, Kejian Chen, Benjamin Scherlag, Isaac Rutel, Kytai Nguyen, Satish Kyriyavar, et al. "Magnetic Targeting of Therapeutics." In ASME 2010 First Global Congress on NanoEngineering for Medicine and Biology. ASMEDC, 2010. http://dx.doi.org/10.1115/nemb2010-13022.

Full text
Abstract:
Multiple formulations of nano-sized particles, capsules, dendrimers, lipids, ceramics and genetic materials are being investigated in multiple labs for delivery of therapeutic moieties to targeted tissues. Interest is driven by reducing health care costs while increasing therapeutic efficacy and cost of treatment. One technology, magnetic targeting, incorporates iron oxide nanoparticles, to target nanomedicine payloads, down the gradients of external magnetic fields. When iron oxide crystal domains are less than ∼20–40 nm, particles become superparamagnetic (SPION), that is exhibit no remanent induction but very high magnetic susceptibility in the presence of an external magnetic field. Thus, targeting can be vectored by magnetic lines of flux. Particles can be pulled out of the microcirculation and across membranes into tissues. Two target organs that can employ magnetic targeting are the heart (epicardium) and inner ear (cochlea).
APA, Harvard, Vancouver, ISO, and other styles
3

Pires, Gabriel Natan, Ksdy Maiara Moura Sousa, Thábita Maganete, Paula Villena Redondo, and Renata Redondo Bonaldi. "SleepUp, a Digital Therapeutics Platform for Insomnia." In XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.296.

Full text
Abstract:
Background: Cognitive-Behavioral Therapy for Insomnia (CBTi) is the gold-standard treatment for chronic insomnia. Although effective, CBTi is not easily accessible due to a shortage of specialized professionals and high treatment costs. Online CBTi (CBTi-O) has been proposed as a more accessible and affordable treatment option. CBTi and CBTi-O are equally effective, and some apps have already been approved by regulatory agencies in USA (Somryst™) and UK (Sleepio™). Objetives: SleepUp is a digital therapeutics solution for insomnia, intended to provide evidence-based treatment in an easily accessible format. Methods: The treatment program is based on CBTi-O, composed by seven therapeutic modules (sleep hygiene, relaxation and meditation, psychoeducation, stimulus control, cognitive restructuring, sleep restriction and paradoxical intention). Users are monitored with a sleep log and validated questionnaires assessing insomnia symptoms, sleepiness, sleep quality and sleep hygiene. Additional therapy modules are included, encompassing mindfulness and other meditation techniques. For refractory cases or for those with comorbidities, remote appointments with medical doctors and psychologists specialized in sleep medicine are available. Results: SleepUp is an early-stage startup and its solutions for sleep and insomnia are being constantly developed and improved. The app is already available in Brazil and USA, both for Android™ and IOS™ devices. Preliminary results demonstrate that the treatment is effective, reducing insomnia symptoms in 28%, (n=1700), improving sleep hygiene scores in 32% (n=100) and increasing sleep efficiency in 16% (n=2500). Conclusion: SleepUp aims at providing a more accessible alternative to the treatment of insomnia, based on CBTI-O, an effective and safe therapeutic approach.
APA, Harvard, Vancouver, ISO, and other styles
4

Harris, Claire. "SP0171 THE NEW COMPLEMENT THERAPEUTICS." In Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. http://dx.doi.org/10.1136/annrheumdis-2019-eular.8492.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Lee, Uichin, Gyuwon Jung, Sangjun Park, Eun-Yeol Ma, Heeyoung Kim, Yonggeon Lee, and Youngtae Noh. "Data-driven Digital Therapeutics Analytics." In 2023 IEEE International Conference on Big Data and Smart Computing (BigComp). IEEE, 2023. http://dx.doi.org/10.1109/bigcomp57234.2023.00093.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Swaan, Abel, Berrend B. G. Muller, Rob A. A. van Kollenburg, Daniel M. de Bruin, Dick H. J. C. M. Sterenborg, Jean J. M. C. H. de la Rosette, Ton G. van Leeuwen, and Dirk J. Faber. "One to one correlation of needle based optical coherence tomography with histopathology: a qualitative and quantitative analysis in 20 prostatectomy specimens (Conference Presentation)." In Therapeutics and Diagnostics in Urology, edited by Hyun Wook Kang and Kin Foong Chan. SPIE, 2017. http://dx.doi.org/10.1117/12.2250119.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Heidari, Andrew E., Kyungjin Oh, and Zhongping Chen. "Using optical coherence tomography to detect bacterial biofilms on foley catheters (Conference Presentation)." In Therapeutics and Diagnostics in Urology, edited by Hyun Wook Kang and Kin Foong Chan. SPIE, 2017. http://dx.doi.org/10.1117/12.2251242.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Pham, Ngot T., Seul Lee Lee, Yong Wook Lee, and Hyun Wook Kang. "Temperature monitoring with FBG sensor during diffuser-assisted laser-induced interstitial thermotherapy (Conference Presentation)." In Therapeutics and Diagnostics in Urology, edited by Hyun Wook Kang and Kin Foong Chan. SPIE, 2017. http://dx.doi.org/10.1117/12.2251369.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Lurie, Kristen L., Robin Guay Lord, Caroline Boudoux, Eric J. Seibel, and Audrey K. Ellerbee. "Miniaturized rapid scanning, forward-viewing catheterscope for optical coherence tomography (Conference Presentation)." In Therapeutics and Diagnostics in Urology, edited by Hyun Wook Kang. SPIE, 2016. http://dx.doi.org/10.1117/12.2213077.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Smith, Gennifer T., Kristen L. Lurie, Dimitar V. Zlatev, Joseph C. Liao, and Audrey K. Ellerbee. "Multimodal, 3D pathology-mimicking bladder phantom for evaluation of cystoscopic technologies (Conference Presentation)." In Therapeutics and Diagnostics in Urology, edited by Hyun Wook Kang. SPIE, 2016. http://dx.doi.org/10.1117/12.2213242.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Therapeutics"

1

Pitt iGEM, Pitt iGEM. Living Skin Therapeutics. Experiment, June 2014. http://dx.doi.org/10.18258/2764.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Pacifici, Maurizio. Preventative Therapeutics for Heterotopic Ossification. Fort Belvoir, VA: Defense Technical Information Center, October 2014. http://dx.doi.org/10.21236/ada612073.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Chakraborty, Srijani. The Dawn of RNA Therapeutics. Spring Library, December 2020. http://dx.doi.org/10.47496/sl.blog.19.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Lillo, Antonietta. Preparedness: surveillance, diagnostics, and therapeutics. Office of Scientific and Technical Information (OSTI), September 2023. http://dx.doi.org/10.2172/2005766.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Prasad, Rajeev Ram. Physiotherapy, Gamification and Digital Therapeutics. Ames (Iowa): Iowa State University, May 2024. http://dx.doi.org/10.31274/cc-20240624-1123.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Papisov, Mikhail. Viral Oncolytic Therapeutics for Neoplastic Meningitis. Fort Belvoir, VA: Defense Technical Information Center, July 2012. http://dx.doi.org/10.21236/ada609948.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Tortorella, Domenico, and Veronika Redmann. Discovery and Testing of Ricin Therapeutics. Fort Belvoir, VA: Defense Technical Information Center, June 2012. http://dx.doi.org/10.21236/ada564153.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Kuruppu, Kumudu D. Viral Oncolytic Therapeutics for Neoplastic Meningitis. Fort Belvoir, VA: Defense Technical Information Center, July 2012. http://dx.doi.org/10.21236/ada566647.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Mao, Hai-Quan. Vesicant Therapeutics Collaborative Core Research Program. Fort Belvoir, VA: Defense Technical Information Center, December 2012. http://dx.doi.org/10.21236/ada581049.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Kuruppu, Kumudu D. Viral Oncolytic Therapeutics for Neoplastic Meningitis. Fort Belvoir, VA: Defense Technical Information Center, July 2013. http://dx.doi.org/10.21236/ada592240.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Therapeutics' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography